Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$433000.0.

  • Zevra Therapeutics' Tax Provisions changed N/A to -$433000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year change of. This contributed to the annual value of $15.4 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Zevra Therapeutics' Tax Provisions stood at -$433000.0.
  • Zevra Therapeutics' 5-year Tax Provisions high stood at $15.4 million for Q4 2024, and its period low was -$786000.0 during Q4 2022.
  • Moreover, its 5-year median value for Tax Provisions was $15000.0 (2021), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Tax Provisions plummeted by 247500.0% in 2023, and later soared by 304142.86% in 2025.
  • Over the past 5 years, Zevra Therapeutics' Tax Provisions (Quarter) stood at $34000.0 in 2021, then crashed by 2411.76% to -$786000.0 in 2022, then surged by 122.52% to $177000.0 in 2023, then skyrocketed by 8584.18% to $15.4 million in 2024, then tumbled by 102.82% to -$433000.0 in 2025.
  • Its Tax Provisions stands at -$433000.0 for Q3 2025, versus $2.2 million for Q2 2025 and $1.2 million for Q1 2025.